NOD2/RIG-I Activating Inarigivir Adjuvant Enhances the Efficacy of BCG Vaccine Against Tuberculosis in Mice

NOD2/RIG-I Activating Inarigivir Adjuvant Enhances the Efficacy of BCG Vaccine Against Tuberculosis in Mice

Tuberculosis (TB) caused by Mycobacterium tuberculosis (MTB) kills about 1.5 million people each year and the widely used Bacille Calmette-Guérin (BCG) vaccine provides a partial protection against TB in children and adults. Because BCG vaccine evades lysosomal fusion in antigen presenting cells (AP...

Full description

Bibliographic Details
Main Authors: Arshad Khan, Vipul K. Singh, Abhishek Mishra, Emily Soudani, Pearl Bakhru, Christopher R. Singh, Dekai Zhang, David H. Canaday, Anjaneyulu Sheri, Seetharamaiyer Padmanabhan, Sreerupa Challa, Radhakrishnan P. Iyer, Chinnaswamy Jagannath
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-12-01
Series:Frontiers in Immunology
Subjects:
tuberculosis
BCG vaccine
inarigivir
adjuvants
NOD2
RIG-I
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2020.592333/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2020.592333/full

Similar Items